RAD completes A$12.5 M placement and launches A$6 M SPP
Filed with ASX · · 8 pages · English
Summary by 6ix AI
Radiopharm Theranostics Limited has successfully completed a significant capital raising, which includes an institutional placement and a Share Purchase Plan for existing shareholders, aiming to raise substantial funds for its ongoing projects. The filing outlines the terms of the capital raising, including the issuance of attaching options to investors, subject to shareholder approval.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Radiopharm Theranostics Limited on 6ix
In the deck
Story so far
Earlier from Radiopharm Theranostics
- Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy
- RAD Achieves Partial Response in Phase 1 Trial of RAD204
- Radiopharm Theranostics Reports Business Update
- Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer Research 2026
- Radiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain Metastases
Later from Radiopharm Theranostics
- Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan
- Application for quotation of securities - RAD
- Notice Under Section 708A
- Prospectus
- Target market determination (TMD)
Follow Radiopharm Theranostics into a list and get an email when it puts out news.
Follow Radiopharm Theranostics